These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Bhavnani SM; Rubino CM; Ambrose PG; Drusano GL Clin Infect Dis; 2010 Jun; 50(12):1568-74. PubMed ID: 20462352 [TBL] [Abstract][Full Text] [Related]
4. Observational retrospective single-centre study in Japan to assess the clinical significance of serum daptomycin levels in creatinine phosphokinase elevation. Ando M; Nishioka H; Nakasako S; Kuramoto E; Ikemura M; Kamei H; Sono Y; Sugioka N; Fukushima S; Hashida T J Clin Pharm Ther; 2020 Apr; 45(2):290-297. PubMed ID: 31696963 [TBL] [Abstract][Full Text] [Related]
5. Patient Case Report Daptomycin Holiday-A Daptomycin Dosing Strategy for Asymptomatic Increases in Creatine Phosphokinase Levels. Koh L; Shah PJ; Aly S J Pharm Pract; 2022 Feb; 35(1):148-151. PubMed ID: 32924753 [TBL] [Abstract][Full Text] [Related]
6. Safety outcomes with high-dose daptomycin in patients with acute kidney injury and/or end-stage renal disease. Vlashyn OO; Lorenz AM; Sobhanie MM; Smith JM; Bond M; Wardlow L J Clin Pharm Ther; 2021 Apr; 46(2):363-368. PubMed ID: 33016513 [TBL] [Abstract][Full Text] [Related]
7. Incidence of elevated creatine phosphokinase between daptomycin alone and concomitant daptomycin and statins: A systematic review and meta-analysis. Samura M; Takada K; Hirose N; Kurata T; Nagumo F; Koshioka S; Ishii J; Uchida M; Inoue J; Enoki Y; Taguchi K; Tanikawa K; Matsumoto K Br J Clin Pharmacol; 2022 May; 88(5):1985-1998. PubMed ID: 34902879 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of impact of statin use on development of CPK elevation during daptomycin therapy. Berg ML; Estes LL; Dierkhising RA; Curran B; Enzler MJ Ann Pharmacother; 2014 Mar; 48(3):320-7. PubMed ID: 24321853 [TBL] [Abstract][Full Text] [Related]
10. Muscle pain associated with daptomycin. Veligandla SR; Louie KR; Malesker MA; Smith PW Ann Pharmacother; 2004 Nov; 38(11):1860-2. PubMed ID: 15367725 [TBL] [Abstract][Full Text] [Related]
11. Musculoskeletal safety outcomes of patients receiving daptomycin with HMG-CoA reductase inhibitors. Bland CM; Bookstaver PB; Lu ZK; Dunn BL; Rumley KF; Antimicrob Agents Chemother; 2014 Oct; 58(10):5726-31. PubMed ID: 25022580 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of daptomycin in patients with renal impairment: a multicenter retrospective analysis. Kullar R; McClellan I; Geriak M; Sakoulas G Pharmacotherapy; 2014 Jun; 34(6):582-9. PubMed ID: 24658897 [TBL] [Abstract][Full Text] [Related]
13. Factors affecting creatine phosphokinase elevation during daptomycin therapy using a combination of machine learning and conventional methods. Imai S; Kashiwagi H; Sato Y; Miyai T; Sugawara M; Takekuma Y Br J Clin Pharmacol; 2022 Mar; 88(3):1211-1222. PubMed ID: 34436795 [TBL] [Abstract][Full Text] [Related]
14. [New drugs; daptomycin]. van Bronswijk H; Dubois EA; van Dissel JT; Cohen AF Ned Tijdschr Geneeskd; 2007 Dec; 151(50):2777-8. PubMed ID: 18232197 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations. Bhavnani SM; Ambrose PG; Hammel JP; Rubino CM; Drusano GL Antimicrob Agents Chemother; 2015 Dec; 60(3):1600-7. PubMed ID: 26711755 [TBL] [Abstract][Full Text] [Related]
16. Decreasing the probability of creatine phosphokinase elevations: clinical considerations for daptomycin dosing in obese patients. Donovan BJ; Mohr JF; Knapp AG; Eisenstein BI Clin Infect Dis; 2010 Oct; 51(8):989; author reply 989-90. PubMed ID: 20858080 [No Abstract] [Full Text] [Related]
19. Observational study to determine the optimal dose of daptomycin based on pharmacokinetic/pharmacodynamic analysis. Yamada T; Ooi Y; Oda K; Shibata Y; Kawanishi F; Suzuki K; Nishihara M; Nakano T; Yoshida M; Uchida T; Katsumata T; Ukimura A J Infect Chemother; 2020 Apr; 26(4):379-384. PubMed ID: 31836287 [TBL] [Abstract][Full Text] [Related]
20. Risk of muscle toxicity events for daptomycin with and without statins: Analysis of the Japanese Adverse Event Report database. Yamada T; Mitsuboshi S; Suzuki K; Nishihara M; Uchiyama K Basic Clin Pharmacol Toxicol; 2021 Sep; 129(3):268-272. PubMed ID: 34117712 [No Abstract] [Full Text] [Related] [Next] [New Search]